The current treatment landscape for back of the eye disorders is characterized by the presence of blockbuster Novel Drugs, such as Lucentis® and Eylea®, and various other therapeutic options. Despite the success of these therapies, their invasive mode of administration, high dosage frequency and other drug related side effects, are some of the drawbacks that have an adverse impact on their therapeutic potential and adoption. Further, there are no treatment approaches available for a number of ophthalmological indications, such as dry age related macular degeneration (dry AMD), retinitis pigmentosa (RP) and leber congenital amaurosis. In order to overcome these challenges, various stakeholders are engaged in the development of novel therapeutic approaches. With the entry of several start-ups that are driving the innovation in this domain, the pipeline has several novel product candidates in various stages of development.
A Robust and Steadily Growing Pipeline Holds Significant Promise
With 7 commercialized drugs and close to 170 clinical / preclinical molecules, the field has evolved significantly over time and has several promising candidates
Molecules Vary Across Therapy Types, Mechanisms and Routes of Administration
The growing pipeline primarily features monotherapies, with diverse mechanisms of action and different routes of administration
North America and Europe are the Key Research Hubs
Over 80% of the drug developers are located in North America and Europe; however, within the Asia Pacific region, Japan has emerged as a popular hub
Innovations, such as Bionic Eye, have Shown Remarkable Potential
Bionic eye technology has grabbed significant traction in the treatment of vision loss owing to degenerative retinal diseases, such as RP
Novel Technology Platforms and Delivery Systems are Amongst the Key Focus Areas
Over 50 companies are specifically engaged in developing technology platforms and systems to address known challenges related to drug delivery
Life Cycle Management Strategies are Already Quite Popular
Companies are considering various life cycle management strategies in order to ensure prolonged patent protection for their proprietary product candidates
The Overall Market is Poised to Witness Ongoing Growth …
Driven by encouraging initiatives, the overall promise is likely to be well distributed across multiple therapeutic indications and drug classes
… as Products with Novel Mechanisms Gain Popularity
Companies developing product candidates with novel mechanisms of action and routes of administration will gain significant traction during this time period
To know more please click here. For any queries / suggestions or if you’d like to get access to the full research results, please do not hesitate to contact us at firstname.lastname@example.org.
For further information on this domain, check our report here.